ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO, Neil Warma, will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 p.m. ET in New York.

ProMIS specializes in developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The fireside chat will be accessible via live webcast through the Events page on the company's website and will remain available for at least 30 days after the event.

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:30 p.m. ET in New York, NY.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and initiated a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.

For further information:

Visit us at www.promisneurosciences.com.

Please submit media inquiries to info@promisneurosciences.com.

For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200

FAQ

When is ProMIS Neurosciences (PMN) presenting at the Guggenheim Securities SMID Cap Biotech Conference 2025?

ProMIS Neurosciences will participate in a fireside chat at the conference on Wednesday, February 5, 2025, at 1:30 p.m. ET in New York.

What diseases does ProMIS Neurosciences (PMN) focus on treating?

ProMIS Neurosciences focuses on developing treatments for neurodegenerative diseases including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA).

How can investors access ProMIS Neurosciences' (PMN) presentation at the Guggenheim Conference?

Investors can access the live webcast of the fireside chat through the Events page on ProMIS Neurosciences' website at www.promisneurosciences.com. The recording will be available for at least 30 days following the event.

What is the main technology focus of ProMIS Neurosciences (PMN)?

ProMIS Neurosciences focuses on the generation and development of antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases.